Full Press Release Details
KAZIA PROVIDES OVERVIEW
RELATED PRESENTATIONS FROM THE SOCIETY OF
NEURO-ONCOLOGY 2023 ANNUAL MEETING
21 November 2023 Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide key highlights
of the clinical and preclinical paxalisib related presentations given by key thought leaders at the Society of Neuro-Oncology 2023 Annual Meeting. The 2023 SNO Annual Meeting was another successful event with the latest advances in clinical
trials, diagnosis and treatment of pediatric and adult patients with CNS malignancies, stated Dr. John Friend, CEO Kazia. We are highly encouraged with the preliminary overall survival data from the PNOC022 clinical study that we
believe will provide an alternative to the current therapies considered as standard of care.
Key paxalisib highlights from the meeting:
Friday, November 17th
Combining ONC201 and paxalisib for the treatment of diffuse midline glioma (DMG); the preclinical results underpinning the international Phase II clinical
trial (NCT05009992).
Presenter: Evangeline R. Jackson; University of Newcastle, NSW, Australia
Exploiting the genetic dependency on PI3K/mTOR signaling for the treatment of H3-altered Diffuse Midline Glioma
Presenter: Ryan Duchatel, PhD; University of Newcastle, NSW, Australia
Phase I study of paxalisib and radiotherapy for CNS disease harboring PI3K pathway mutations: pilot analysis of
circulating tumor DNA for patient eligibility confirmation and post-treatment response
Presenter: Brandon Imber, MD, Memorial Sloan Kettering Cancer
PNOC022: a combination therapy trial using an adaptive platform design for patients with diffuse midline gliomas (DMGs) at initial diagnosis, post-radiation
therapy and at time of therapy
Presenter: Sabine Mueller, MD, UCSF, San Francisco, USA
This announcement was authorized for release by Dr. John Friend, CEO.
About Kazia Therapeutics Limited
Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant
inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase II
study in glioblastoma reported promising signals of clinical activity in 2021, and a pivotal study, GBM AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, DMGs, and primary CNS lymphoma,
with several of these having reported encouraging interim data.
Paxalisib was granted Orphan Drug Designation for glioblastoma by the US Food and Drug Administration (US FDA) in February 2018, and Fast Track Designation
for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July
Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical
data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy with immuno-oncology agents. A Phase I study in advanced solid tumors commenced recruitment in November 2021.
Forward-Looking Statements
This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as may, will, estimate, future, forward, anticipate, or other similar words. Any
statement describing Kazia s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements
regarding: the timing for results and data related to Kazia s clinical and preclinical trials, and Kazia s strategy and plans with respect to its programs, including paxalisib and EVT801, as well as any potential future indications and
timing for the release of interim or final data for such programs. Such statements are based on Kazia s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and
that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials
and product development, including the risk that preliminary or interim data may not reflect final results, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are
described more fully in Kazia s Annual Report, filed on form 20-F with the United States Securities and Exchange Commission (SEC), and in subsequent filings with the SEC. Kazia undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as
of the date of this announcement.